SCHEMBL4308355

SCHEMBL4308355

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.70
NT5E P21589 1/20 0.65
FUT5 Q11128 1/20 0.65
KRAS P01116 3/20 0.64
ENPP1 P22413 2/20 0.61
P2RY1 P47900 2/20 0.61
P2RY12 Q9H244 1/20 0.61
P2RY6 Q15077 2/20 0.60
P2RX3 P56373 2/20 0.60
P2RX1 P51575 1/20 0.60
P2RY11 Q96G91 1/20 0.60
P2RX4 Q99571 1/20 0.60
P2RY2 P41231 1/20 0.60
P2RY4 P51582 1/20 0.60
RNASEL Q05823 2/20 0.59
POLB P06746 1/20 0.57
DCPS Q96C86 1/20 0.57
IMPDH2 P12268 4/20 0.56
IMPDH1 P20839 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1622486 0.99 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL1622482 0.99 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL234673 0.97 TGM2 (0.70) TGM2NT5EFUT5KRASENPP1
SCHEMBL21067995 0.97 TGM2 (0.70) TGM2NT5EFUT5KRASENPP1
SCHEMBL21256201 0.97 TGM2 (0.70) TGM2NT5EFUT5KRASENPP1
SCHEMBL23176397 0.97 TGM2 (0.70) TGM2NT5EFUT5KRASENPP1
SCHEMBL877839 0.97 TGM2 (0.70) TGM2NT5EFUT5KRASENPP1
SCHEMBL4011876 0.96 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL6512071 0.96 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1
SCHEMBL1533928 0.96 TGM2 (0.69) TGM2NT5EFUT5KRASENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117521944-A Data statistics and processing method for investment decision of distributed photovoltaic power generation project 国网甘肃省电力公司定西供电公司 2024-02-06 CN claimed
US-20230390409-A1 FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES AVACTA LIFE SCIENCES LIMITED (GB) 2023-12-07 US claimed
CN-117042808-A FAP activated serum half-life extending therapeutic conjugates 阿瓦克塔生命科学有限公司 2023-11-10 CN claimed
EP-4237012-A1 FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES Avacta Life Sciences Limited (GB) 2023-09-06 EP claimed
CN-115256563-B High-strength fir glued wood beam, preparation method and bending rigidity index determination method 中国林业科学研究院木材工业研究所 2023-03-21 CN claimed
CN-115486824-A Cuff-free continuous blood pressure estimation system based on uncertainty measurement 电子科技大学 2022-12-20 CN claimed
CN-115256563-A High-strength fir glued wood beam, preparation method thereof and flexural rigidity index determination method 中国林业科学研究院木材工业研究所 2022-11-01 CN claimed
CN-111476412-B Photovoltaic power generation cost allocation research method considering carbon footprint and transaction 国网福建省电力有限公司泉州供电公司 2022-07-08 CN claimed
WO-2022094262-A1 FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES AVACTA LIFE SCIENCES LIMITED (GB) 2022-05-05 WO claimed
US-20260034244-A1 MODIFIED FUSION PROTEIN AND USE THEREOF PANOLOS BIOSCIENCE INC (KR) 2026-02-05 US disclosed
US-20250369986-A1 APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University (CN) 2025-12-04 US disclosed
EP-4657069-A1 APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University (CN) 2025-12-03 EP disclosed
EP-4638148-A1 TIRES FOR VEHICLE WHEELS Pirelli Tyre S.p.A. (IT) 2025-10-29 EP disclosed
US-20250269632-A1 LOW STATIC DISCHARGE NON-BLOCKING MULTILAYER BARRIER FILM TAGHLEEF INDUSTRIES INC. 2025-08-28 US disclosed
EP-2511844-B1 X-ray microscope XRPRO SCIENCES INC (US) 2015-08-12 EP disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390409-A1 FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES FAP, FIBP, FUCA2 TGM2 112/4885NT5E 986/4885FUT5 950/4885
US-20260034244-A1 MODIFIED FUSION PROTEIN AND USE THEREOF PGF, VEGFA, FLT1 TGM2 699/4885NT5E 2959/4885FUT5 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.